HOXC9 and gastric cancer: Interestingly, miR-26a has been shown to suppress HOXC9 and inhibits its oncogenic potential and stemness features of self-renewal, suggesting that miR-26a-mediated HOXC9 silencing could be viable for GC therapy [91].